Condition: Psoriatic Plaque · Sponsor: KoBioLabs
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Total Skin and Beauty Dermatology Center | Birmingham, Alabama, United States | — |
| Southern California Dermatology, Inc | Santa Ana, California, United States | — |
| Clinical Science Institute | Santa Monica, California, United States | — |
| Revival Research Institute | Doral, Florida, United States | — |
| Indago Research and Health Center | Hialeah, Florida, United States | — |
| Louisiana Dermatology Associates - Dermatology | Baton Rouge, Louisiana, United States | — |
| Premier Specialist | Kogarah, New South Wales, Australia | — |
| Westmead Hospital | Westmead, New South Wales, Australia | — |
| Veracity Clinical Trials Ltd | Woolloongabba, Queensland, Australia | — |
| Sinclair Dermatology | East Melbourne, Victoria, Australia | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04911751